Last reviewed · How we verify
HSK21542 dose level 2
At a glance
| Generic name | HSK21542 dose level 2 |
|---|---|
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery (PHASE2)
- Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK21542 in Healthy Adult Male Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK21542 dose level 2 CI brief — competitive landscape report
- HSK21542 dose level 2 updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI